MicroRNAs Associated with Overweight and Obesity in Childhood: A Systematic Review

Carlos Andrés Rico Flórez1, Herney Andrés García-Perdomo2, Mildrey Mosquera Escudero3

  • 1School of Basic Sciences, Nutrition Group, Universidad del Valle, Cali, Colombia.

Abstract

Insights

MicroRNAs (miRNAs) show potential as biomarkers for childhood obesity. Specific miRNAs like miR-15b-5p, miR-486-5p, and hsa-miR-122-5p are promising indicators for this condition.

Area of Science:

  • Biochemistry and Molecular Biology
  • Pediatric Endocrinology
  • Genetics

Background:

  • Rising prevalence of overweight and obesity in children globally.
  • MicroRNAs (miRNAs) are key regulators of gene expression.
  • Understanding miRNA involvement in pediatric obesity is crucial.

Purpose of the Study:

  • To review the association between microRNA expression and overweight/obesity in children.
  • To identify specific miRNAs implicated in pediatric obesity development.

Main Methods:

  • Systematic literature search across major databases (Medline, EMBASE, LILACS, CENTRAL).
  • Inclusion of clinical trials, cohort, case-control, and cross-sectional studies on children.
  • Exclusion of studies on adults, animal models, and in silico research.

Main Results:

  • Seven studies involving 684 children were analyzed.
  • Sixty-five miRNAs were associated with overweight and obesity.
  • miR-122, miR-15b, miR-191-5p, miR-222, and miR-486 were frequently reported; miR-15b-5p, miR-486-5p, and hsa-miR-122-5p emerged as strong candidates.
  • Blood samples were the primary source for miRNA detection.

Conclusions:

  • MicroRNAs are potential biomarkers for obesity in children.
  • A diverse set of miRNAs are linked to pediatric obesity.
  • miR-15b-5p, miR-486-5p, and hsa-miR-122-5p show promise as diagnostic biomarkers for childhood obesity.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
136